凯莱英(002821) - 2020 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2020 was ¥475,496,806.78, a decrease of 0.21% compared to ¥476,494,446.55 in the same period last year[8] - Net profit attributable to shareholders increased by 17.34% to ¥108,029,889.53 from ¥92,063,799.35 year-on-year[8] - The net profit after deducting non-recurring gains and losses was ¥93,342,503.90, up 16.33% from ¥80,239,049.36 in the previous year[8] - Basic and diluted earnings per share increased by 17.50% to ¥0.47 from ¥0.40 year-on-year[8] - The company reported a total comprehensive income of 110,265,879.79 CNY for the quarter, compared to 95,879,096.52 CNY in the previous year, indicating a growth of around 15%[41] - The total operating revenue for the first quarter was 119,349,601.73 CNY, an increase from 102,899,107.24 CNY in the previous year, representing a growth of approximately 15.5%[40] - The net profit for the first quarter reached 108,029,889.53 CNY, compared to 92,063,799.35 CNY in the same period last year, marking an increase of about 17.3%[40] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 34.93% to ¥49,207,245.92 compared to ¥75,617,344.15 in the same period last year[8] - Cash received from operating activities decreased by 77.18% to ¥1,362,572.64, attributed to a reduction in other receivables[16] - The company's cash and cash equivalents decreased to ¥380,914,652.63 from ¥435,252,214.16, indicating a decline in liquidity[30] - The cash inflow from operating activities amounted to ¥590,399,514.40, slightly up from ¥588,254,842.79 in the previous period[47] - The cash outflow from operating activities totaled ¥541,192,268.48, an increase from ¥512,637,498.64 year-over-year[48] - The cash and cash equivalents at the end of the period were ¥362,991,966.61, down from ¥598,029,313.74 in the previous period[49] - The net increase in cash and cash equivalents was -¥51,392,687.01, compared to -¥61,941,730.19 in the prior period[49] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,839,819,411.87, an increase of 2.16% from ¥3,758,736,367.43 at the end of the previous year[8] - Total liabilities amounted to CNY 682,523,881.63, down from CNY 713,232,174.09[32] - The company's retained earnings increased to CNY 1,805,596,685.22 from CNY 1,697,566,795.69[33] - The total liabilities for the first quarter of 2020 were CNY 721,803,350.68, with current liabilities at CNY 707,264,693.11 and non-current liabilities at CNY 14,538,657.57[59] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 18,404[12] - ASYMCHEM LABORATORIES, INCORPORATED held the largest share, with a holding ratio of 39.61% and 91,647,220 shares[12] - Net assets attributable to shareholders rose by 3.67% to ¥3,157,295,530.24 from ¥3,045,504,193.34 at the end of the previous year[8] - Owner's equity increased to CNY 3,157,295,530.24 from CNY 3,045,504,193.34[33] Research and Development - Research and development expenses increased by 48.33% to ¥54,845,685.02, reflecting strategic investments in pharmaceutical technology and an increase in R&D personnel[16] - Research and development expenses amounted to 54,845,685.02 CNY, up from 36,975,781.74 CNY, reflecting a significant increase of approximately 48.3% year-over-year[40] Government Support and Subsidies - The company received government subsidies amounting to ¥20,114,458.03 during the reporting period[9] Financial Management - The company reported a significant decrease in financial expenses by 185.46%, resulting in a negative amount of -¥8,621,600.07, mainly due to RMB to USD exchange rate fluctuations[16] - The financial expenses showed a significant improvement, with a net income of -8,621,600.07 CNY compared to 10,088,475.30 CNY in the previous year, indicating a positive change in financial management[40] Market Strategy - The company is focusing on expanding its market presence and enhancing its product offerings through increased investment in R&D and strategic initiatives[40]